Investors

News Releases

Date Title  
Toggle Summary POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 1, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective
Toggle Summary Pozen Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US $350 Million Capital Commitment from Deerfield-Led Syndicate toFund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management
Toggle Summary POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Sep. 14, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced that James P. Tursi, M.D. will be appointed Chief Medical Officer of POZEN , effective October 1, 2015 . Dr. Tursi will report to Adrian Adams , Chief Executive Officer of POZEN , and will be responsible
Toggle Summary POZEN Appoints Scott Charles Senior Vice President of Finance
Charles to Serve as Chief Financial Officer of Aralez Following Completion of Merger with Tribute Pharmaceuticals CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced
Toggle Summary POZEN Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Jun. 2, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited , a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer
Toggle Summary POZEN Inc. to Announce Third Quarter 2015 Results on November 9, 2015
Company to host call at 11:00 a.m. ET CHAPEL HILL, N.C. --(BUSINESS WIRE)--Oct. 26, 2015-- POZEN Inc. (NASDAQ: POZN) today announced that the Company plans to release results for the third quarter 2015 on Monday, November 9, 2015 , before the opening of the U.S. markets.
Toggle Summary POZEN Reports First Quarter 2015 Results
CHAPEL HILL, N.C. --(BUSINESS WIRE)--May 8, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015 . Corporate Highlights Q1 2015 was the fourth consecutive quarter of
Toggle Summary POZEN Reports Fourth Quarter and Year End 2014 Results
- Reports Annual Net Income of $19.7 Million , Including VIMOVO Royalty of $21.1 Million - - Updates Anticipated Commercialization Timing - CHAPEL HILL, N.C. --(BUSINESS WIRE)--Mar. 9, 2015-- POZEN Inc. (NASDAQ: POZN) , a pharmaceutical company committed to transforming medicine that transforms
Toggle Summary POZEN Reports Second Quarter 2015 Results
-Strategic Merger with Tribute Pharmaceuticals Expected to Close in the 4Q 2015- -Commercialization Plans for YOSPRALA TM Underway- CHAPEL HILL, N.C. --(BUSINESS WIRE)--Aug. 10, 2015-- POZEN Inc. (NASDAQ:POZN) , today announced results for the second quarter ended June 30, 2015 .

Copyright West LLC. Minimum 15 minutes delayed.